TCG CROSSOVER MANAGEMENT LLC
Q4 2024 Form 13-F
PALO ALTO, CALIFORNIA
CIK 0001839948
· CRD 311718
· SEC-registered investment adviser
$1.0B Reported Value Total
TCG CROSSOVER MANAGEMENT, LLC reports 2 total accounts under management (AUM). There are 2 discretionary accounts valued at $1,799,709,770, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $3.8B gross asset value
Other: $3.8B
Source: Form ADV filed 2026-05-29
Reported value
$1.0B
Quarter over quarter
-23.7%
Holdings
38
Top-10 concentration
52.0%
Key People
Form ADV owners & control persons
Chen Ming Yu
MANAGING PARTNER
Craig David Skaling
CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2024 13F record
Q4 2024 13F filing summary
| Period of report | December 31, 2024 |
|---|---|
| Filed | February 14, 2025 |
| Form | 13F-HR |
| Reported value | $1.0B |
| Positions | 38 |
| Change in reported value | -13.3% |
| New positions | 5 |
| Exited positions | 3 |
| Position turnover | 19.5% |
| Top-10 concentration | 52.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
57 | $3.5B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
54 | $4.2B |
|
Q1 2026 13F
Filed May 15, 2026
|
49 | $3.5B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
43 | $3.0B |
|
Q3 2025 13F
Filed Nov 17, 2025
|
40 | $2.0B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
37 | $875.5M |
|
Q1 2025 13F
Filed May 14, 2025
|
37 | $733.1M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
38 | $1.0B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
36 | $1.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
32 | $959.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
33 | $1.3B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
29 | $901.7M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
26 | $679.1M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
22 | $609.8M |
|
Q1 2023 13F
Filed May 15, 2023
|
22 | $513.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
21 | $566.6M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
21 | $333.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
22 | $235.4M |
|
Q1 2022 13F
Filed May 16, 2022
|
20 | $249.1M |
|
Q4 2021 13F
Filed Feb 18, 2022
|
15 | $213.6M |
Top 20 holdings · Q4 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CGON CG ONCOLOGY INC | $105.3M | 10.29% |
| 2 | DYN DYNE THERAPEUTICS INC | $62.4M | 6.1% |
| 3 | XNCR XENCOR INC | $56.4M | 5.51% |
| 4 | COGT COGENT BIOSCIENCES INC | $54.3M | 5.31% |
| 5 | CNTA CENTESSA PHARMACEUTICALS PLC | $48.4M | 4.73% |
| 6 | OCUL OCULAR THERAPEUTIX INC | $45.4M | 4.44% |
| 7 | UPB UPSTREAM BIO INC | $44.9M | 4.38% |
| 8 | ABVX ABIVAX SA AMERICAN DEPOSITARY SHARES | $44.3M | 4.33% |
| 9 | SVRA SAVARA INC | $38.0M | 3.71% |
| 10 | TNGX TANGO THERAPEUTICS INC | $33.2M | 3.24% |
| 11 | DNTH DIANTHUS THERAPEUTICS INC | $32.7M | 3.2% |
| 12 | IRON DISC MEDICINE INC | $30.9M | 3.02% |
| 13 | MLYS MINERALYS THERAPEUTICS INC | $30.4M | 2.97% |
| 14 | TRML TOURMALINE BIO INC | $30.0M | 2.93% |
| 15 | GPCR STRUCTURE THERAPEUTICS INC | $28.8M | 2.82% |
| 16 | TYRA TYRA BIOSCIENCES INC | $27.6M | 2.7% |
| 17 | EYPT EYEPOINT PHARMACEUTICALS INC | $26.6M | 2.6% |
| 18 | CDTX Cidara Therapeutics, Inc. | $26.1M | 2.55% |
| 19 | THRD THIRD HARMONIC BIO INC | $25.8M | 2.52% |
| 20 | SLNO SOLENO THERAPEUTICS INC | $24.7M | 2.42% |
Values as reported on the Q4 2024 Form 13F. Every position is in the holdings table below.